International Flavors & Fragrances (IFF)
NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-07
$81.81-1.16%
Close 2026-07-07 · 1-day change
Reading IFF? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IFF free→NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-07
Reading IFF? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IFF free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is contracting — down about 6% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 24% growth a year, above the roughly 2% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIFF's growth depends on maintaining strong performance in a challenging materials sector. Revenue growth has been weak, with a recent earnings beat of 16.8%. It trades at 19× P/E, below the peer median of 23.5×. The market is pricing in more growth than expected, making the valuation look full. If IFF cuts guidance on the next call, it could negatively impact the stock. Peer multiples imply a price about 24% below where it trades. This read is provisional.
Trailing returns as of 2026-07-07. IFF is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering IFF (as of Jul 2026).
Based on 4 Wall Street analysts offering 12-month price targets for IFF in the last 4 months.
A consensus fair price across 12 valuation methods, at three horizons. Current price $81.81. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Advances: Drive financial performance with innovation
Earnings beat indicates strong financial performance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $81.81
The last 12 months of price, then the range of analyst 12-month targets from today’s $81.81.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Drive financial performance with innovation
New product launch enhances innovation efforts.
Advances: Drive financial performance with innovation
Q4 earnings beat and sales rise support financial performance.
Advances: Optimize portfolio through divestitures
Divestiture of cosmetics business aligns with portfolio optimization.
Advances: Optimize portfolio through divestitures
Sale of pharma solutions supports portfolio optimization.